LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 96

Search options

  1. Book: The parasomnias and other sleep related movement disorders

    Thorpy, Michael J.

    2010  

    Title variant The parasomnias and other sleep-related movement disorders
    Author's details ed. by Michael J. Thorpy
    Keywords Parasomnias ; Movement Disorders
    Language English
    Size XIII, 341 S.
    Publisher Cambridge Univ. Press
    Publishing place Cambridge u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT016420751
    ISBN 978-0-521-11157-7 ; 0-521-11157-9
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2010 A 3330 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Recently Approved and Upcoming Treatments for Narcolepsy.

    Thorpy, Michael J

    CNS drugs

    2020  Volume 34, Issue 1, Page(s) 9–27

    Abstract: Narcolepsy is a chronic, disabling neurologic disorder characterised by excessive daytime sleepiness (EDS) and, in up to 60% of patients, cataplexy. Treatments for narcolepsy are aimed at improving wakefulness (e.g. modafinil, armodafinil, stimulants), ... ...

    Abstract Narcolepsy is a chronic, disabling neurologic disorder characterised by excessive daytime sleepiness (EDS) and, in up to 60% of patients, cataplexy. Treatments for narcolepsy are aimed at improving wakefulness (e.g. modafinil, armodafinil, stimulants), reducing cataplexy attacks (e.g. sodium oxybate, venlafaxine), and treating the symptoms of disturbed nocturnal sleep, sleep paralysis and sleep-related hallucinations (e.g. sodium oxybate). In general, medications that increase the release, or inhibit the reuptake, of norepinephrine or dopamine have wake-promoting effects and are useful in managing EDS, whereas medications that inhibit serotonin or norepinephrine reuptake have anticataplectic effects. Modulation of γ-aminobutyric acid B (GABA
    MeSH term(s) Animals ; Central Nervous System Stimulants/pharmacology ; Central Nervous System Stimulants/therapeutic use ; Humans ; Narcolepsy/drug therapy
    Chemical Substances Central Nervous System Stimulants
    Language English
    Publishing date 2020-01-17
    Publishing country New Zealand
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1203800-3
    ISSN 1179-1934 ; 1172-7047
    ISSN (online) 1179-1934
    ISSN 1172-7047
    DOI 10.1007/s40263-019-00689-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4083: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Neuroimaging of sleep and sleep disorders

    Nofzinger, Eric / Maquet, Pierre / Thorpy, Michael J.

    2013  

    Title variant Sleep and sleep disorders
    Author's details ed. by Eric Nofzinger ; Pierre Maquet ; Michael J. Thorpy
    Keywords Sleep Disorders / diagnosis ; Neuroimaging / methods ; Sleep / physiology
    Language English
    Size XVI, 427 S. : Ill., graph. Darst.
    Publisher Cambridge Univ. Press
    Publishing place Cambridge
    Publishing country Great Britain
    Document type Book
    Note Includes bibliographical references and index
    HBZ-ID HT018465868
    ISBN 978-1-107-01863-1 ; 1-107-01863-3
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2014 A 4398 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Brain fog in central disorders of hypersomnolence: a review.

    Rosenberg, Russell / Thorpy, Michael J / Doghramji, Karl / Morse, Anne Marie

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

    2024  Volume 20, Issue 4, Page(s) 643–651

    Abstract: ... Rosenberg R, Thorpy MJ, Doghramji K, Morse AM. Brain fog in central disorders of hypersomnolence: a review. ...

    Abstract Brain fog is an undefined term describing a cluster of symptoms related to fatigue and impaired memory, attention, and concentration. Brain fog or brain fog-like symptoms have been reported in central disorders of hypersomnolence and in a range of seemingly unrelated disorders, including coronavirus disease 2019, major depressive disorder, multiple sclerosis, lupus, and celiac disease. This narrative review summarizes current evidence and proposes a consensus definition for brain fog. Brain fog is prevalent in narcolepsy and idiopathic hypersomnia, with more than three-quarters of patients with either disorder reporting this symptom in a registry study; it has also been reported as particularly difficult to treat in idiopathic hypersomnia. Studies directly evaluating brain fog are rare; tools for evaluating this symptom cluster typically are patient reports, with few objective measures validated in any disorder. Evaluating brain fog is further complicated by confounding symptoms, such as excessive daytime sleepiness, which is a hallmark of hypersomnolence disorders. No treatments specifically address brain fog. The paucity of literature, assessment tools, and medications for brain fog highlights the need for research leading to better disambiguation and treatment. Until a clear consensus definition is established, we propose brain fog in hypersomnia disorders be defined as a cognitive dysfunction that may or may not be linked with excessive sleepiness, related to an underlying neuronal dysfunction, which reduces concentration and impairs information processing, leading to a complaint of lack of clarity of mental thinking and awareness.
    Citation: Rosenberg R, Thorpy MJ, Doghramji K, Morse AM. Brain fog in central disorders of hypersomnolence: a review.
    MeSH term(s) Humans ; Idiopathic Hypersomnia/diagnosis ; Depressive Disorder, Major ; Disorders of Excessive Somnolence/etiology ; Narcolepsy/diagnosis ; Mental Fatigue
    Language English
    Publishing date 2024-01-13
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 2397213-0
    ISSN 1550-9397 ; 1550-9389
    ISSN (online) 1550-9397
    ISSN 1550-9389
    DOI 10.5664/jcsm.11014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6590: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations.

    Morse, Anne Marie / Bogan, Richard K / Roy, Asim / Thorpy, Michael J

    Neurology and therapy

    2024  

    Abstract: Introduction: Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate (SXB). As ... ...

    Abstract Introduction: Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate (SXB). As the indication for oxybate treatment in patients with idiopathic hypersomnia is new and allows for individualized dosing optimization, guidance for beginning LXB treatment is needed. In particular, clinicians may benefit from guidance regarding treatment initiation, dosing/regimen options, potential challenges, and treatment expectations. Additionally, pharmacokinetic profiles differ slightly between both treatments, and further guidance on transitioning from SXB to LXB in patients with narcolepsy may aid clinicians.
    Methods: An expert panel of five sleep specialists was convened to obtain consensus on recommendations for these topics using a modified Delphi process.
    Results: Across two virtual meetings, the panel agreed on 31 recommendations with a high degree of consensus that fell into four overarching topics: (1) introducing LXB to patients; (2) initiating LXB for adult narcolepsy and idiopathic hypersomnia; (3) addressing challenges in using LXB; and (4) transitioning from SXB to LXB. The panel recommended that clinicians provide a clear overview of how LXB works for treating symptoms in narcolepsy or idiopathic hypersomnia, as appropriate for their patients, explain safety aspects, and set expectations prior to initiating LXB treatment. Strategies for initial dosing and regimen are provided. Strategies for adjusting the dose, regimen, timing, and consideration of individual factors were developed for specific instances in which patients may have trouble staying asleep or waking up, as well as guidance for addressing potential adverse events, such as nausea, dizziness, anxiety, and depression. Discussion points based on existing literature and clinical experience were included as relevant for each statement.
    Conclusion: Clinicians may use this resource to guide LXB dosing optimization with patients.
    Language English
    Publishing date 2024-04-25
    Publishing country New Zealand
    Document type Journal Article
    ISSN 2193-8253
    ISSN 2193-8253
    DOI 10.1007/s40120-024-00607-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Book: Sleepiness

    Thorpy, Michael J. / Billiard, Michel

    causes, consequences and treatment

    2011  

    Author's details ed. by Michael J. Thorpy ; Michel Billiard
    Keywords Disorders of Excessive Somnolence ; Schlafstörung
    Subject Agrypnie ; Asomnie ; Insomnie ; Schlaflosigkeit
    Language English
    Size XVIII, 475 S., [8] Bl. : Ill., graph. Darst., 25 cm
    Publisher Cambridge Univ. Press
    Publishing place Cambridge u.a.
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT016696586
    ISBN 978-0-521-19886-8 ; 0-521-19886-0
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2011 A 566 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Book: Neurologic disorders update: current thinking and practices

    Thorpy, Michael J.

    (Neurology ; 64,12, Suppl. 3)

    2005  

    Author's details Michael J. Thorpy, guest ed
    Series title Neurology ; 64,12, Suppl. 3
    Collection
    Language English
    Size S39 S.
    Publisher Lippincott Williams & Wilkins
    Publishing place Hagerstown, Md
    Publishing country United States
    Document type Book
    HBZ-ID HT014447142
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Ui II Zs 153 -64,Suppl.3- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial.

    Thorpy, Michael J / Kushida, Clete A / Bogan, Richard / Ajayi, Akinyemi O / Corser, Bruce C / Gudeman, Jennifer

    Sleep medicine: X

    2024  Volume 7, Page(s) 100109

    Abstract: Background: Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (: Methods: Participants with narcolepsy aged ≥16 years received ON-SXB (1 wk, 4.5 g; 2 wk, 6 g; 5 wk, 7.5 g; 5 wk, 9 g) or placebo. ... ...

    Abstract Background: Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (
    Methods: Participants with narcolepsy aged ≥16 years received ON-SXB (1 wk, 4.5 g; 2 wk, 6 g; 5 wk, 7.5 g; 5 wk, 9 g) or placebo. Percentages of participants with NT1 who had ≥25%, ≥50%, ≥75%, and 100% reductions from baseline in mean number of weekly cataplexy episodes were determined. Two-sided
    Results: Participants with NT1 (ON-SXB, n = 73; placebo, n = 72; modified intent-to-treat population) had a baseline mean number of weekly cataplexy episodes of 18.9 (ON-SXB) and 19.8 (placebo). Of participants receiving the highest doses of ON-SXB (7.5 and 9 g), approximately half had a 50% reduction, one-third had a 75% reduction, and one-tenth had a 100% reduction in their cataplexy episodes vs placebo. Significantly greater proportions of participants receiving ON-SXB vs placebo had respective reductions in weekly cataplexy episodes of ≥25% at weeks 1 (4.5 g;
    Conclusions: A significantly greater proportion of participants receiving ON-SXB vs placebo experienced reductions in weekly cataplexy episodes at all tested doses. Approximately 10% of participants taking the 2 highest ON-SXB doses had complete elimination of their cataplexy.
    Language English
    Publishing date 2024-03-30
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2590-1427
    ISSN (online) 2590-1427
    DOI 10.1016/j.sleepx.2024.100109
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Once-nightly sodium oxybate (FT218) improved symptoms of disrupted nighttime sleep in people with narcolepsy: a plain language summary.

    Roth, Thomas / Thorpy, Michael J / Kushida, Clete A / Horsnell, Matthew / Gudeman, Jennifer

    Journal of comparative effectiveness research

    2023  Volume 12, Issue 12, Page(s) e230133

    Abstract: What is this summary about?: This is a plain language summary of a published article in the journal : What were the results?: Compared to people who took placebo, people who took ON-SXB had fewer number of changes from deeper to lighter sleep stages ... ...

    Abstract What is this summary about?: This is a plain language summary of a published article in the journal
    What were the results?: Compared to people who took placebo, people who took ON-SXB had fewer number of changes from deeper to lighter sleep stages and woke up less during the night. They also reported that they slept better at night and felt more refreshed when waking up in the morning. People with narcolepsy sometimes take alerting agents to help with sleepiness during the day, but alerting agents can cause difficulty sleeping at night. This study showed that people who took ON-SXB had better nighttime sleep even if they were taking alerting agents during the day. The most common side effects of ON-SXB included dizziness, nausea (feeling sick to your stomach), vomiting, headache, and bedwetting.
    What do the results mean?: A once-nightly bedtime dose of ON-SXB is a narcolepsy treatment option for people without the need for a middle-of-the-night dose of sodium oxybate.
    MeSH term(s) Adult ; United States ; Humans ; Sodium Oxybate/therapeutic use ; Sodium Oxybate/pharmacology ; Narcolepsy/drug therapy ; Narcolepsy/complications ; Narcolepsy/diagnosis ; Cataplexy/drug therapy ; Cataplexy/complications ; Cataplexy/diagnosis ; Sleep ; United States Food and Drug Administration
    Chemical Substances Sodium Oxybate (7G33012534)
    Language English
    Publishing date 2023-11-16
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2669725-7
    ISSN 2042-6313 ; 2042-6305
    ISSN (online) 2042-6313
    ISSN 2042-6305
    DOI 10.57264/cer-2023-0133
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Current Understanding of Narcolepsy 1 and its Comorbidities: What Clinicians Need to Know.

    Krahn, Lois E / Zee, Phyllis C / Thorpy, Michael J

    Advances in therapy

    2021  Volume 39, Issue 1, Page(s) 221–243

    Abstract: Narcolepsy is a chronic neurologic disorder associated with the dysregulation of the sleep-wake cycle that often leads to a decreased quality of life and results in a considerable health burden. There is often a delay to diagnosis of narcolepsy, mainly ... ...

    Abstract Narcolepsy is a chronic neurologic disorder associated with the dysregulation of the sleep-wake cycle that often leads to a decreased quality of life and results in a considerable health burden. There is often a delay to diagnosis of narcolepsy, mainly due to the lack of recognition of this disorder. One of the main factors hindering the diagnosis of narcolepsy is the association of comorbidities, which include other sleep disorders, psychiatric disorders, cardiovascular disorders, and metabolic disorders. The signs and symptoms of these comorbidities often overlap with those of narcolepsy, and some of the medications used for their treatment may obscure the symptoms of narcolepsy, leading to a delay in diagnosis. This review is targeted to clinicians unaccustomed to working with sleep disorders and aims to increase recognition and improve the management of narcolepsy.
    MeSH term(s) Cataplexy/diagnosis ; Cataplexy/epidemiology ; Comorbidity ; Humans ; Narcolepsy/complications ; Narcolepsy/diagnosis ; Narcolepsy/drug therapy ; Quality of Life
    Language English
    Publishing date 2021-12-11
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-021-01992-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2101: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top